Pricing Log in Create free account
Saturday 17 October 2026 Export NGVT’s income statement to Excel — free account

Ingevity Corporation

NGVT Basic Materials Specialty Chemicals

In the quarter to June 2026, revenue fell 5.25%, EPS grew 125.4%, free cash flow fell 136.1% and total debt fell 14.5%, each against the same quarter a year earlier.

69.82 0.72 −1.02%
Market cap
$2.4B
P/E
45.3×
Fwd P/E
18.5×
Dividend yield
—
F-score
6/9
Altman Z
1.84
Beneish M
−4.00
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.76
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — 1 — — 3 — —
Insider Ownership 2.22%

Capital & Financial Ratios $m

Market Cap 2,430.00
Revenue 1,160.30
Net Income 54.00
Free Cash Flow 154.90
Net Debt 873.00
Current Ratio 1.61 (at or above 1.5: strong)
Debt/Equity 22.52 (above 2: weak)
P/E ratio 45.34 (above 35: high)
Fwd P/E 18.50
P/S ratio 2.09
P/B ratio 51.64 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 17.66% (at or above 15%: strong)
Next Y EPS Growth 12.76%
Next Y revenue growth (4.93%) (below 0%: weak)
Next 5Y EPS Growth 14.28%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.9×, against a ten-year median of 2.9×; over the ten years it ranged from 1.4× in 2016 to 5.3× in 2019.
P/E against its own 10 years 85.29%
10-year low 10-year high
P/S against its own 10 years 52.43%
10-year low 10-year high
P/B against its own 10 years 93.23%
10-year low 10-year high
EV/Sales against its own 10 years 45.25%
10-year low 10-year high
EV/FCF against its own 10 years 33.04%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 96 68 78 183
Receivables 182 132 127 156
Inventory 309 196 186 154
Other — — — —
659 493 454 544
2023 2024 2025 Q'26
Payables 158 95 92 88
ST’ Debt — — — —
Other — — — —
363 264 341 338

Compound Annual Growth %

10y 5y 3y
Sales 2.00% (0.81%) (11.21%)
Cash Flow 16.45% (1.23%) 1.86%
Earnings 0.00% 0.00% 0.00%
Book Value (24.86%) (45.92%) (65.09%)

Revenue $m

Mar Jun Sep Dec Year
’26 258 314 — — —
’25 248 332 333 255 1,168
’24 340 391 334 136 1,200
’23 393 482 446 — 1,216
’22 383 420 482 384 1,668
’21 320 358 377 336 1,392
’20 288 271 332 326 1,216
Fiscal quarters ending in the months shown.
value withheld pending a data check

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (14) — — —
’25 25 79 130 97 331
’24 (12) 30 47 65 129
’23 5 48 105 46 205
’22 24 91 100 99 313
’21 51 66 100 76 293
’20 60 49 90 153 352
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (24) — — —
’25 19 67 114 77 277
’24 (29) 12 29 40 51
’23 (20) 27 72 17 95
’22 (3) 61 64 49 171
’21 34 42 75 39 190
’20 41 34 74 122 270
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 1.66 1.00 — — —
’25 0.56 (4.02) 1.18 (2.37) (4.61)
’24 (1.54) (7.81) (2.95) 0.46 (11.85)
’23 1.35 0.97 0.69 (3.23) (0.15)
’22 1.55 1.54 1.98 0.41 5.50
’21 1.20 1.10 (0.11) 0.74 2.95
’20 1.08 0.49 1.69 1.23 4.48
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 23.00 51.01 66.57 72.59 24.92 63.43 56.31 36.66 30.90 28.49

Analyst estimates 2026–2028

Powerpack
High 55.43 80.18 106.59 120.41 88.02 89.55 79.79 90.81 56.30 61.77
People
People Employees 1,500 1,500 1,750 1,850 1,750 1,850 2,050 1,700 1,600 1,500
Revenue/emp, $m 0.61 0.65 0.65 0.70 0.69 0.75 0.81 0.72 0.75 0.78
Income, $m
Income, $m Revenue 908 972 1,134 1,293 1,216 1,392 1,668 1,216 1,200 1,168
Gross margin, % 30.21 33.83 36.77 37.28 38.28 36.85 34.17 36.61 38.73 39.53
EBT 87 175 222 228 235 163 270 130 (140) (142)
EBT margin, % 9.58 17.98 19.57 17.63 19.33 11.70 16.16 10.70 (11.71) (12.17)
Net income 44 145 182 184 181 118 212 (5) (430) (167)
Depreciation 39 40 57 85 100 110 109 123 457 290
Per share, $
Per share, $ Revenue 21.57 23.08 26.97 30.93 29.42 34.95 43.70 33.31 33.04 32.23
Earnings 0.83 3.00 4.03 4.39 4.51 2.97 5.54 (0.15) (11.85) (4.61)
Cash flow 3.04 4.14 5.99 6.60 8.53 7.37 8.21 5.62 3.54 9.14
Capex (1.35) (1.25) (2.23) (2.75) (1.99) (2.61) (3.73) (3.01) (2.14) (1.49)
Free cash flow 1.69 2.89 3.76 3.85 6.54 4.76 4.48 2.61 1.40 7.65
Book value 3.20 6.60 8.06 12.70 15.54 16.92 18.29 17.30 5.37 0.82
Shares, m 42 42 42 42 41 40 38 36 36 36
Valuation, ×
Valuation, × P/E 66.48 23.72 20.77 19.95 16.79 24.31 12.87 0.00 0.00 0.00
P/S 2.47 3.07 3.10 2.83 2.57 2.05 1.63 1.41 1.23 1.84
P/B 16.64 10.75 10.39 6.88 4.87 4.24 3.88 2.72 7.58 72.18
EV/Sales 2.97 3.45 3.71 3.75 3.42 2.77 2.47 2.48 2.31 2.78
EV/FCF 37.89 27.55 26.57 30.10 15.38 20.31 24.14 31.69 54.33 11.71
Cash, $m
Cash, $m Operating cash flow 128 174 252 276 352 293 313 205 129 331
Capex (57) (53) (94) (115) (82) (104) (142) (110) (78) (54)
Free cash flow 71 122 158 161 270 190 171 95 51 277
Balance, $m
Balance, $m Working capital 158 216 239 248 405 456 380 296 229 113
Total debt 489 453 741 1,228 1,267 1,250 1,473 1,383 1,340 1,161
Net debt 458 366 664 1,172 1,010 975 1,396 1,287 1,272 1,083
Shareholders’ equity 135 278 339 531 642 674 698 631 195 30
Returns, %
Returns, % ROA 4.37 14.36 15.07 10.63 8.11 0.00 8.13 (0.20) (18.52) (9.10)
ROIC 10.72 18.56 15.75 9.93 10.34 11.01 9.62 6.54 (1.81) (2.47)
ROE 10.80 61.33 54.85 42.25 30.93 0.00 30.84 (0.81) (104.11) (148.60)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Ingevity Corporation vs peers in Specialty Chemicals (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ASH Ashland Inc. $3.3B 62.4× 24.9× +7.34% (above 0%: growing) n/m +5.26% (above 0%: growing) 34.21% 8.65% Compare
FUL H. B. Fuller Company $2.8B 14.1× 16.8× +5.17% (above 0%: growing) +18.19% (above 0%: growing) −58.41% (below 0%: shrinking) 33.22% 12.07% Compare
HWKN Hawkins, Inc. $2.8B 33.8× 36.3× +7.64% (above 0%: growing) −3.55% (below 0%: shrinking) +30.29% (above 0%: growing) 23.44% 12.25% Compare
KWR Quaker Houghton $2.7B 27.9× 25.2× +10.17% (above 0%: growing) n/m −43.19% (below 0%: shrinking) 35.53% 7.62% Compare
WDFC WD-40 Company $2.7B 30.3× 34.0× +24.35% (above 0%: growing) +45.45% (above 0%: growing) −13.28% (below 0%: shrinking) 56.59% 20.67% Compare
NGVT Ingevity Corporation $2.4B 45.3× 18.5× −5.25% (below 0%: shrinking) n/m −136.08% (below 0%: shrinking) 44.25% 19.13%
IOSP Innospec Inc. $2.4B 19.7× 16.3× +11.76% (above 0%: growing) +32.98% (above 0%: growing) −63.16% (below 0%: shrinking) 28.14% 8.08% Compare
MTX Minerals Technologies Inc. $2.0B — (loss-making) 12.4× +3.69% (above 0%: growing) n/m +5.92% (above 0%: growing) 24.40% (40.17%) Compare
CC The Chemours Company $1.9B — (loss-making) 16.9× −1.49% (below 0%: shrinking) n/m +128.00% (above 0%: growing) 17.98% (13.39%) Compare
Median of peers $2.7B 29.1× 20.9× +7.49% +25.59% −4.01% 30.68% 8.37%

All 60 Specialty Chemicals stocks →

Ingevity Corporation (NGVT) key facts

  • Ingevity Corporation (NGVT) is a Specialty Chemicals company in the Basic Materials sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, NGVT traded at $69.82, a market capitalization of $2.4 billion.
  • Return on equity was −148.6% and debt-to-equity 22.52.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 1.84 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Ingevity Corporation (NGVT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/NGVT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com